Impact of Delirium on Distress, Health-Related Quality of Life, and Cognition 6 Months and 1 Year after Hematopoietic Cell Transplant  by Basinski, James R. et al.
From the
versit
ton;
Cente
Ohio
Biobe
Cente
C.M. Alfa
of Ca
Institu
Financial d
Correspon
of Psy
ton S
Seattl
Received M
 2010 El
1083-8791
doi:10.101
824Impact of Delirium on Distress, Health-Related Quality
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James R. Basinski,1 Catherine M. Alfano,2 Wayne J. Katon,1
Karen L. Syrjala,1,3 Jesse R. Fann1,3Delirium commonly occurs during myeloablative hematopoietic cell transplantation (HCT). Little is known
about how delirium during the acute phase of HCT affects long-term distress, health-related quality of life
(HRQOL), and neurocognitive functioning. This prospective, cohort study examines these outcomes at 6
months and 1 year in 90 patients undergoing HCT. Patients completed a battery assessing distress, HRQOL,
and subjective neuropsychological functioning before receiving their first HCTas well as at 6 months and 1
year. Patients with a delirium episodewithin the 4 weeks after HCT had significantly more distress and fatigue
at 6 months (P\.004) and at 1 year (P\.03), compared with patients without delirium. At 1 year, patients
with delirium also had worse symptoms of depression and post traumatic stress (P\.03). Patients with de-
lirium had worse physical health on the SF-12 at 6 months (P\.03) and worse mental health on the SF-12 at 1
year (P\.03). At both 6 months and 1 year, patients with delirium after HCTreported worse memory (P\
.009) and executive functioning (P\.006). Delirium during the acute phase of HCT is significantly associated
with persistent distress, decreased HRQOL, and subjective neurocognitive dysfunction at both 6 months and
1 year.
Biol Blood Marrow Transplant 16: 824-831 (2010)  2010 Elsevier Inc. All rights reserved.KEY WORDS: Delirum, Stem cell transplantation, Distress, Quality of life, Cognition, OutcomesINTRODUCTION
Delirium is a common neuropsychiatric complica-
tion of hematopoietic cell transplantation (HCT), re-
ported in up to 50% of patients in the first 4 weeks
posttransplantation [1,2]. The high rates of delirium
in patients undergoing HCT appear linked to having
a severe acute systemic disease and being exposed to
treatment interventions with deliriogenic or cognitive
effects. Potential treatments that may precipitate1Department of Psychiatry and Behavioral Sciences, Uni-
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/$36.00
6/j.bbmt.2010.01.003delirium include: psychoactive medications such as
opioid analgesics, sedatives, corticosteroids, and
anticholinergics [3], as well as total body irradiation
(TBI) [4] and resultant infections [5].
By definition, delirium is characterized by a revers-
ible disturbance of consciousness and change in cogni-
tion or perception [6]. It is independently associated
with significant morbidity, mortality, and functional
decline across multiple populations [7]. Deleterious ef-
fects onmortality [8,9], length of hospital stay [10], and
performance status [8] have been noted in hospitalized
cancer patients who develop delirium. To our knowl-
edge, no studies have examined the effects of delirium
on longer term outcomes of cognition, distress, and
health-related quality of life (HRQOL) in patients
with either cancer or those who received HCT.
A prospective, longitudinal study of patients un-
dergoing HCT indicates that physical, psychological,
and vocational recovery begins during the first year
posttransplantation and continues over at least the
next 3 to 5 years [11]. The same research group also
found that patients in the first post-HCT year had per-
sistent declines in grip strength and motor dexterity,
but otherwise returned to pretransplantation levels of
cognition [12]. In contrast, a prospective study of neu-
rocognitive changes in the first 20 months in patients
with hematologic malignancies being treated with
Biol Blood Marrow Transplant 16:824-831, 2010 825Impact of Delirium 6 Months and 1 Year after HCTHCT compared to a reference group of patients re-
ceiving nonmyeloablative therapies found persistent
declines in attention and executive function in addition
to psychomotor function in both groups [13]. It re-
mains unclear whether delirium contributes to the
risk of persistent functional and cognitive decrements
in HCT patients.
The goal of this study was to investigate the asso-
ciation of delirium during acute phase treatment with
distress, HRQOL, and cognition 6 months and 1
year after HCT. Fifty percent of this previously de-
scribed cohort had a delirium episode during the first
4 weeks after HCT [2]. Previous outcome results
from this cohort have demonstrated delirium’s adverse
impact on depression, anxiety, and fatigue at 30 days as
well as worse anxiety, fatigue, distress, HRQOL, exec-
utive functioning, attention, and processing speed at
80 days [14]. In the current analysis, we hypothesized
that patients who had experienced a delirium episode
in the acute phase of HCTwould have worse cognitive
functioning, distress, and HRQOL at the extended
follow-up points of 6 months and 1 year compared to
patients who had not experienced delirium.PATIENTS AND METHODS
Patients
Ninety patients between the ages of 22 to 62 years
were recruited before their first myeloablative allo-
genic or autologous bone marrow or peripheral blood
HCT at the FredHutchinson Cancer Research Center
(FHCRC).
Procedures
Study procedures for this cohort have been previ-
ously reported [2]. The FHCRC institutional review
board approved the protocol and all study procedures.
All study patients received and signed written in-
formed consent. Patients completed a comprehensive
battery before transplantation measuring distress,
HRQOL, and neuropsychological functioning. The
results of the readministration of a subset of this bat-
tery at 30 days and the full battery again at 80 has
been previously reported [14]. At 6 months and 1
year, patients again completed a subset of this battery.
From 7 days pretransplantation until 30 days post-
transplantation, study investigators or trained research
nurses screened patients 3 times per week with a brief
delirium assessment battery, targeted to the same time
each day (Monday, Wednesday, and Friday).
Independent Variables
We measured delirium using the Delirium Rating
scale (DRS), a 10-item, clinician-rated scale (score
range: 0-32) that rates delirium severity over 24 hoursusing sources including patient interview, mental sta-
tus examination, medical history and tests, and collat-
eral observation from nursing staff and family [15].We
defined a delirium episode as a DRS score .12 on at
least 2 of 3 consecutive assessments.Dependent Variables
Distress
The Symptom Checklist-90-R (SCL-90) is a stan-
dardized self-report inventory of psychologic symp-
toms (score range: 0-4; higher scores 5 greater
distress), which has been used with cancer patients
[16,17]. It has been shown to have high reliability
and validity in medical patients. We report on the
depression and anxiety subscales.
The Profile of Mood States (POMS) Fatigue sub-
scale is the 7-item subset of a valid and reliable scale of
mood disturbance (score range: 0-4; higher scores 5
greater fatigue) widely used in cancer patients [18].
The Cancer and Treatment Distress scale is the
mean of a 29-item self-report questionnaire (score
range: 0-3; higher scores 5 greater distress), devel-
oped in the HCT population, that measures cancer
specific distress distinct from general anxiety or
depression [11].
The Post Traumatic Stress scale was developed by
the fourth author (K.L.S.) for use in HCT patients. It
is similar to the Patient Health Questionnaire (PHQ)
[19] as a self-report of symptoms for diagnosing
PTSD corresponding toDiagnostic and Statistical Man-
ual IV psychiatric criteria [6]. The measure includes 11
symptom items scored for frequency from 0 5 not at
all to 65 several times a day, and 1 item on overall im-
pact rated from 05 these things have not happened to
me to 5 5 severely disturbing, they really have an
impact on how I feel and what I do.
HRQOL
The 12 item version of the Short-Form Health
Survey (SF-12) measures physical and mental
HRQOL using 2 standardized summary measures of
physical and mental health (higher scores 5 better
functioning) [20].
Neuropsychological functioning
TheNeurobehavioral Rating scale (NBRS) is a 27-
item structured self-report questionnaire of executive
functioning measuring behavioral disturbance includ-
ing insight, disinhibition, and impaired attention
(score range: 0-10; higher scores5more severe behav-
ioral disturbance) [21].
The Modified Memory Questionnaire (MMQ) is
a 35-item measure of subjective memory function
(score range: 0-4; higher scores 5 greater memory
dysfunction) [22].
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Potential confounders (see Table 1) obtained from
the centralized medical database were categorized into
the following 4 blocks of variables:
1. Demographics included age and sex.
2. Baseline medical and transplantation variables included
severity of disease (cancer diagnosis and stage),
donor cell type, and graft-versus-host disease
(GVHD) prophylaxis.
3. Systemic chemotherapy before transplantation and radi-
ation included type of prior chemotherapy and dose
of conditioning with TBI.
4. Long-term posttransplantation complications included
extent of chronic GVHD (cGVHD).Statistical Analyses
To assess whether differential attrition biased the
study results, t-tests or chi-square tests evaluated
whether there were demographic or clinical differ-
ences, including delirium episode status, between pa-
tients who were present in the current analyses and
those who had dropped out of the study.
Next, we used t-tests to compare unadjustedmeans
on outcomes for the delirium episode and no-delirium
episode groups. Finally, we used linear regression
modeling to calculate betas (B), standard errors
(SEs), and 95% confidence intervals (CI) for the rela-
tionships between delirium and 6-month and 1-year
outcomes, adjusting for potential confounding factors.
Confounding was evaluated separately for each model
by sequentially entering the 4 blocks of potential
confounders (demographics, baseline medical and
transplantation variables, pretransplantation chemo-
therapy and radiation, and long-term posttransplanta-
tion complications) and then iteratively eliminating
nonconfounding variables from each block by moni-
toring the change in the beta coefficient for delirium
for $10% [23,24]. Models did not adjust for the
pretransplantation level of the outcome variable for 2
reasons: (1) potential effects of delirium on outcomes
would have been obscured by shared variation
between delirium and the pretransplantation level of
each outcome and by the high correlations (eg, 0.7)
between the 6-month or 1-year outcomes and the
pretransplantation level of each outcome; and (2)
recent work has suggested that adjustment for
baseline levels of outcome variables can induce bias
in observational studies [25].RESULTS
Of the 90 original patients enrolled, 30 patients
had died and 8 patients were unavailable because of re-
lapse by 1 year (Figure 1). Six of the patients unavail-
able for follow-up at 6 months were subsequentlytested at 1 year. Few significant differences were found
between patients present in the current analyses com-
pared to those who had dropped out. There was a non-
significant trend for a lower percent of patients who
had experienced a delirium episode to be available
for testing at 1 year compared to those who had not ex-
perienced a delirium episode (64.4% versus 51.6%; P
5 .20). The 2 groups differed significantly in diagnosis
(P 5 .009): a higher percent of survivors with chronic
myelogenous leukemia, breast carcinoma, ovarian car-
cinoma, or non-Hodgkin lymphoma were available at
1 year (71.1%, 72.7%, 83.3%), whereas a lower per-
cent of those surviving after acute lymphoblastic or
myelogenous leukemia, and myelodysplastic syn-
drome or multiple myeloma were available (32.0%,
40.0%). Patients tested at 1 year were also significantly
more likely to have extensive GVHD than those un-
available (75.5% veresus 24.5%, P 5 .03).
The baseline demographic and medical character-
istics of the 52 patients who were available for follow-
up at 6 months and 1 year are listed in Table 1. The
sample was predominantly white, younger than 55
years, and included more men than women. The
most common diagnosis was chronicmyeloid leukemia
(51.9%). Most patients received allogeneic bone mar-
row transplants. More than half of the sample had re-
ceived pretransplant conditioning with TBI, and over
70% of patients had extensive cGVHD.Diagnosis, do-
nor type, and GVHD prophylaxis were significantly
different between patients with a delirium episode
and patients without a delirium episode.
The unadjustedmeans on 6-month and 1-year out-
comes by delirium episode status are presented in
Table 2. Without adjustment for confounding, the
delirium group had more fatigue and cancer and treat-
ment distress, and worse neuropsychological function-
ing at 6 months compared to patients who had not
experienced a delirium episode. The delirium group
also showed similar differences in unadjusted scores
at 1 year.
The results of linear regression models predicting
outcomes at both time points, adjusted for potential
confounders are listed in Table 3. At 6 months post-
transplantation, after adjusting for confounding factors,
patients who had experienced a previous delirium epi-
sode reported significantly more fatigue (P 5.004)
and cancer and treatment distress (P5 .002), andworse
physical HRQOL scores (P 5 .03) compared to those
who had not experienced a delirium episode. Patients
who had experienced a delirium episode reported
significantly worse neurocognitive functioning as
measured by both the NBRS (P 5 .006) and the
MMQ (P5 .009).
At 1 year following transplantation, after adjusting
for confounding factors, patients who had experienced
a previous delirium episode reported greater mental
health distress, including depression (P 5 .03),
Table 1. Characteristics of Patients Available at 1 year (n 5 52)
No Delirium Episode Delirium Episode*
P-Value
(n 5 29) (n 5 23)
n (%) n (%)
Age at study entry .28
22-35 years 12 (41.4) 5 (21.7)
36-45 years 9 (31.0) 7 (30.4)
46-55 years 6 (20.7) 6 (26.1)
56-62 years 2 (6.9) 5 (21.7)
Sex .11
Male 19 (65.5) 10 (43.5)
Female 10 (34.5) 13 (56.5)
Race .30
White 27 (93.1) 23 (100%)
Hispanic 1 (3.4) 0 (0)
Other 1 (3.4) 0 (0)
Diagnosis .01
CML 17 (58.6) 10 (43.5)
ALL or AML 5 (17.2) 3 (13.0)
BR or OV 1 (3.4) 7 (30.4)
MDS or MM 4 (13.8) 0 (0)
NHL 2 (6.9) 3 (13.0)
Disease stage† .47
Less advanced 15 (51.7) 10 (43.5)
More advanced 13 (44.8) 13 (56.5)
Source of stem cells .06
Bone marrow 24 (82.8) 13 (56.5)
Stem cell 5 (17.2) 10 (43.5)
Donor type .02
Allogeneic 27 (93.1) 15 (65.2)
Autologous 2 (6.9) 8 (34.8)
GVHD prophylaxis .03
CSP or tacrolimus and methotrexate 22 (75.9) 12 (52.2)
Methotrexate alone 2 (6.9) 8 (43.8)
RFT5.dgA 3 (10.3) 3 (13.0)
BC-3 2 (6.9) 0 (0)
Systemic chemotherapy before HCT .34
Hydroxyurea only or none 13 (44.8) 7 (30.4)
Interferon with or without hydroxyurea 6 (20.7) 4 (17.4)
Chemo other than interferon or hydroxyurea 9 (31.0) 12 (52.2)
Cranial irradiation or intrathecal chemotherapy before HCT .80
Yes 3 (10.3) 3 (13.0)
None 25 (86.2) 20 (87.0)
Conditioning with total-body irradiation .62
#1200 cGy 7 (24.2) 7 (30.4)
>1200 cGy 9 (31.0) 6 (26.1)
None 13 (44.8) 10 (43.5)
Chronic GVHD extent .22
Extensive 23 (79.3) 14 (60.9)
Limited or none 6 (20.7) 9 (39.1)
GVHD trreatment medications .48
Glucocorticoids 22 (75.9) 20 (87.0)
Other or none 7 (24.1) 3 (13.0)
Relapse at 6 months .69
Relapse since baseline 2 (6.9) 1 (4.3)
No relapse 27 (93.1) 22 (95.7)
Relapse at 1 year .62
Relapse since 6 months 3 (10.3) 1 (4.3)
No relapse 26 (89.7) 22 (95.7)
Mean (SD) Mean (SD)
Pretransplantation Charlson Comorbidity Score 2.3 (1.1) 2.4 (1.3) .72
CML indicates chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BR, breast carcinoma; OV, ovarian
carcinoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; GVHD, graft-versus-host disease; CsA, cyclospor-
ine; RFT5.dgA, CD25-specific immunotoxin; BC-3, CD3-specific antibody; HCT, hematopoietic cell transplantation.
*Delirium episode group includes patients with 2 of 3 consecutive assessments with DRS > 12.
†Less advanced disease was defined as acute lymphoblastic leukemia or acute myelogenous leukemia in first remission; chronic myelogenous leukemia in
a chronic phase; non-Hodgkin lymphoma in first remission, untreated first recurrence, or second remission. More advanced disease included all other
stages of these diseases, all other types of hematologic malignancies, breast carcinoma equal to or greater than stage II, and ovarian carcinoma.
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90 patients presenting for first myeloablative allogeneic or 
autologous marrow or peripheral blood hematopoietic 
cell transplantation enrolled 
  45 with delirium episode (50%) 
Withdrawn from Study (n=38) 
Died (n=27) 
Could not participate because of severe illness 
(n=11), including relapse (n=7) 
Subsequently available for 1 year follow-up (n=6) 
Withdrawn from Study (n=6) 
Died (n=3) 
Could not participate because of severe illness 
(n=3), including relapse (n=1) 
1 year follow-up 
  52 patients1
 23 with prior delirium episode 
6 month follow-up 
  52 patients 
 21 with prior delirium episode 
1
 Six of the patients unavailable for follow-up at 6 months because of severe illness were
subsequently available at one year.
Figure 1. Patient participation in study.
828 Biol Blood Marrow Transplant 16:824-831, 2010J. R. Basinski et al.posttraumatic stress disorder (PTSD) symptoms
(P5 0.03), and lower scores on the mental component
of the SF-12 (P5 .04) aswell as greater fatigue (P5 .02)
and cancer and treatment distress (P 5 .03). Patients
who had experienced a previous delirium episode also
reported significantly worse neurocognitive function-
ing on the NBRS (P5 .004) and theMMQ (P5 .005).DISCUSSION
The present study examines the association of de-
lirium in the acute phase of myeloablative HCT with
later outcomes of distress, HRQOL, and neurocogni-
tive functioning, in this case at 6 months and 1 year
after transplantation. Small but statistically significant
differences in specific domains of all 3 categories of
outcomes emerged at both 6 months and 1 year for
patients experiencing delirium, thus supporting our
initial hypotheses.
Patients in the current study with a delirium epi-
sode reported significantly decreased memory and
neurobehavioral functioning at both 6 months and,to a lesser magnitude, 1 year compared to those with-
out delirium. The clinical significance of the NBRS
and MMQ scores seen in this study is not well estab-
lished. However, comparison of the 6-month and
1-year scores to 80-day scores seen in our earlier
work [14] (delirium and nondelirium groups at 80
days with respective NBRS scores of 1.8 and 1.2 and
MMQ scores of 0.7 and 0.4), indicates that the magni-
tude of score differences between the delirium and
no-delirium groups remains consistent or increases
across time.
Previous research of long-term delirium outcomes
on cognition has largely focused on older populations,
and has shown a robust association between delirium
and subsequent cognitive deterioration including de-
mentia in patients hospitalized for general medical
conditions over 1 year [26], 2 years [27], and 3 years
[28], as well as elderly patients hospitalized for hip
fracture over the 2 subsequent years [29]. Interestingly,
analyses [30,31] of 2 of the aforementioned studies
[26,29] found that patients with recovery of delirium
symptoms at 2 months had no increased risk of
cognitive decline.
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Biol Blood Marrow Transplant 16:824-831, 2010 829Impact of Delirium 6 Months and 1 Year after HCTAlthough patients undergoing HCT appear to
report baselinemild tomoderate worsening of distress,
HRQOL, and/or cognition [32], their younger age is
associated with a lower prevalence of dementia then
the older study populations. The continuing aggres-
siveness of the cancer and intensity of treatment and
supportive care following resolution of a delirium
episode may be contributory factors for the persistent
cognitive declines in patients undergoing HCT
following resolution of their acute delirium episode.
Similar to the pathophysiology of delirium itself,
the etiology of its association with persistent cognitive
decline remains unclear but is likely multifactorial.
Possible mechanisms with both acute and chronic
impacts include oxidative stress [33], exacerbation in
inflammatory cascades [34], and decreased brain perfu-
sion [35]. Ongoing use ofmedications including opioid
analgesics, sedatives, corticosteroids, calcineurin in-
hibitors, and anticholinergics could both cause or
worsen delirium aswell as possibly have long term toxic
effects on the brain, thereby affecting cognition [36].
The diffuse range of differences in distress, HRQOL,
and cognition reported by patients following delirium
inHCT does not definitively localize the pathophysio-
logical mechanisms to specific brain regions, circuits,
or neurotransmitter systems.Our results are consistent
with a growing body of evidence associating depressive
and cognitive symptoms, potentially through the link
between executive dysfunction [37] and decreased
prefrontal lobe perfusion [38].
We found delirium to be associated with cancer
and treatment distress as well as fatigue at both time
points, although of decreased magnitude at 1 year.
We similarly found delirium status to be associated
with reports of significantly more severe depression
and PTSD-related symptoms at 1 year. These results
correspond to a recent review article reporting a rela-
tionship between in-hospital delirium and subsequent
depression and/or anxiety in 5 of 8 studies of multiple
patient populations [39].
Although the underlying etiology for the emer-
gence of greater depression symptoms in our study at
1 year is unclear, it is possibly related to worse mental
rather than physical functioning. Patients experiencing
delirium during acute phase treatment reported worse
physical HRQOL at 6 months compared to patients
in the no-delirium group, but by 1 year there was no
significant difference between the groups. Conversely,
patients with a delirium episode during acute phase
treatment reported worse mental functioning at
1 year, but not at 6 months.
Past studies examining the impact of delirium on
HRQOL have largely focused on functional outcomes
in older populations hospitalized with a medical
condition or hip fracture, with outcomes including am-
bulation, activities of living, and independent activities
of daily living. Results have indicated a largely negative
Table 3. Adjusted Linear Regression Models Predicting 6-Months and 1-Year Outcomes from Delirium Episode Status During
Acute Treatment
6-Month Outcomes 1-Year Outcomes
Delirium Episode versus
No-Delirium Episode B
(SE)*
95% Confidence
Interval P- Value
Delirium Episode versus
No-Delirium Episode B
(SE)*
95% Confidence
Interval P-Value
Distress
Symptoms Checklist Depression subscale 0.26 (0.15) 20.05, 0.57 .09 0.31 (0.14) a,h 0.04, 0.59 .03
Symptoms Checklist Anxiety subscale 0.20 (0.15) a 20.11, 0.51 .20 0.17 (0.12) a,h 20.07, 0.41 .17
Profile of Mood States Fatigue subscale 0.72 (0.24) a 0.24, 1.20 .004 0.49 (0.21) d 0.08, 0.91 .02
Cancer and treatment distress 0.42 (0.13) a 0.17, 0.68 .002 0.28 (0.12) a 0.03, 0.52 .03
Posttraumatic Stress Disorder Scale — — — 0.66 (0.33) g 0.13, 1.20 .02
Health-related quality of life
SF-12 Physical Component Summary 27.26 (3.31) d 213.92, 20.60 .03 22.40 (3.01) b,d,f,g 28.47, 3.66 .43
SF-12 Mental Component Summary 21.47 (2.5) a,f,h 26.59, 3.66 .57 24.75 (2.21) a 29.19, 20.32 .04
Neuropsychological Functioning
Neurobehavioral Rating Scale 1.00 (0.35) a 0.30, 1.70 .006 0.60 (0.31) a 0.33, 1.59 .004
Modified Memory Questionnaire 0.36 (0.13) 0.09, 0.63 .009 0.31 (0.12) 0.11, 0.59 .005
B indicates beta coefficient; SE, standard error for the beta coefficient.
Results in boldface type are statistically significant at P < .05.
a–hPotential confounders were evaluated in blocks. The superscript letters a–h denotes which variables were found to be significant confounders and
were adjusted for in the indicated model:Demographics: age,a sex,b
Baseline medical and transplantation variables: severity of disease,c cell type,d GVHD prophylaxis,e
Total body irradiation,f or systemic chemotherapy before transplantation,g
Long-term posttransplantation complications: extent of chronic graft-versus-host disease.h
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at time lengths varying from 6 months to 2 years
[26,29,31] although1 study showedno relationship [40].
Our study had several limitations. Although follow-
up at both 6months and 1 yearwas high for patients still
healthy enough to participate, the study population had
severe illness related to hematologic malignancies. By 6
months, almost half of the original 90 patients were un-
available for follow-up because of unavoidable reasons
including death, severe illness, or relapse. Patients avail-
able at 1 year in both the delirium and no delirium
groups were significantly more likely to have cGVHD,
and theremayhavebeenotherunmeasured factors lead-
ing to information bias. All outcomemeasures are stan-
dardized, valid, and reliable, but also subjective. We
lack objective or observational measures for neurocog-
nitive outcomes. Except for PTSD, which was only
measured at 12 months, we measured all outcomes at
6 months and 12 months. Additional unmeasured vari-
ables affecting vulnerability for delirium, for example,
personality traits, physical/emotional reserve, cerebral
atherosclerosis, aswell as deliriumprecipitating factors,
such as long-term effects of anticholinergic medica-
tions, could be associated with residual confounding
at both outcome points.
Our findings suggest that the occurrence of delir-
ium during the acute phase of HCT may have adverse
long-term effects on distress, HRQOL, and cognition.
These findings further highlight the importance of
recognizing and treating delirium as a complication
of HCT with potential long-term consequences,
rather than as a strictly acute and transient side effect
of HCT. Future research should aim to replicate these
findings in larger myeloablative and nonmyeloablativeHCT populations and examine in more detail
a broader range of conditioning regimens. The mech-
anisms by which delirium may affect long-term out-
comes needs further study. Our results add to the
literature suggesting the importance of more attention
to detection and treatment of acute delirium as a focus
of sound clinical care for survivors of HCT.ACKNOWLEDGMENTS
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